BACE1 and Alzheimer disease: As observed before, benzothiazole and benzimidazole are the benzazoles most evaluated in relation to AD, principally as AChE, BChE, BACE1, MAO-A, and MAO-B inhibitors, as well as for their antiradical properties (Figure 8).